


PHARMACEUTICAL 2022

CytomX Therapeutics Inc. Rank 304 of 475







PHARMACEUTICAL 2022

CytomX Therapeutics Inc. Rank 304 of 475



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 96% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -197%, being 79% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	310,301
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	106,316
Liabilities, Non-Current	143,716
Other Assets	22,201
Other Compr. Net Income	-195
Other Expenses	0
Other Liabilities	0
Other Net Income	-83,632
Property and Equipment	5,960
Research and Development	114,194
Revenues	69,573
Selling, General and Administrative Expense	39,160

Output Variable	Value in 1000 USD
Assets	339,411
Liabilities	250,032
Expenses	153,354
Stockholders Equity	89,379
Net Income	-167,413
Comprehensive Net Income	-167,510
Economic Capital Ratio	-197%